View Older Stories
-
RBC Capital Downgrades Humana (HUM) to Sector Perform
-
Humana (HUM) PT Lowered to $252 at Guggenheim
-
Humana (HUM) PT Lowered to $180 at Evercore ISI
-
Humana shares fall as 2026 earnings guidance disappoints investors
-
Humana (HUM) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY26 EPS Guidance
-
Humana Q4 Preview
-
Humana (HUM) call put ratio 1.1 calls to 1 put into expected release of quarter results on February 12
-
Humana (HUM) call put ratio 1 call to 1.7 puts into quarter results
-
Guggenheim Reiterates Buy Rating on Humana (HUM)
-
Morgan Stanley Downgrades Humana (HUM) to Underweight
-
Health insurers slide after 2027 Medicare Advantage payments proposal underwhelms
-
Piper Sandler: 'We Would Be Buyers of ALHC, CVS on Selloff, UNH Post-EPS'
-
Humana (HUM) call put ratio 1 call to 1.5 puts
-
After-hours movers: Humana, UnitedHealth, CVS Health, Sanmina and more
-
Trump Administration Proposes Flat Rates for Medicare Advantage, CMS and White House Say -- WSJ
-
Humana (HUM) PT Lowered to $310 at Jefferies
-
Humana partners with Atlas Oncology for Medicare cancer care in two states
-
Humana (HUM) call put ratio 1 call to 1.1 puts
-
Cigna Corp. (CI) And Others Watch Amid Circulating Online Research Report
-
UnitedHealth, Humana, Cigna fall after Trump comments on insurance pricing
-
Trump: Insurance Companies Need to Get Their Prices Down
-
Humana announces leadership changes as insurance chief plans retirement
-
BofA Comments on GLP-1s and Potential Pressure Ahead
-
KeyBanc Reiterates Sector Weight Rating on Humana (HUM)
-
Humana (HUM) May Have Limited Near-term Upside - Cantor Fitzgerald
-
Jefferies Upgrades Humana (HUM) to Buy
-
Mark Cuban in talks with Humana on pharmacy partnership
-
Humana reaffirms 2025 earnings guidance ahead of investor meetings
-
Plus Therapeutics secures Humana coverage for brain cancer test
-
Humana (HUM) PT Lowered to $310 at Mizuho
-
Humana (HUM) PT Lowered to $253 at Jefferies
-
Humana (HUM) Tops Q3 EPS by 41c; affirms guidance
-
Important Notice Long-Term Shareholders of Humana Inc. (HUM): Grabar Law Office Investigates Claims on Your Behalf
-
Humana expands veteran-focused Medicare plans with free mental health care
-
Humana announces 2026 Medicare plans for veterans with mental health focus
-
Goldman Sachs Starts Humana (HUM) at Sell
-
Humana Loses Second Lawsuit To Reverse Medicare Bonus Cuts - Bloomberg
-
Cantor Fitzgerald Reiterates Neutral on Humana (HUM), Notes 2026 MA Margin Improvement
-
Cantor Fitzgerald Reiterates Neutral on Molina Healthcare (MOH), Highlights 2026 Stars Progress
-
Mizuho Positive on CVS Health (CVS): 'We believe this is a positive for CVS'
-
Humana (HUM) PT Raised to $313 at Wolfe Research
-
Humana maintains 2025 earnings guidance amid Medicare star ratings update
-
Humana announces 2026 Medicare Advantage plan changes
-
Cantor Fitzgerald Reiterates Neutral Rating on Humana (HUM)
-
Trump: Working On Lowering Cost Of Health Insurance
-
Evercore ISI Starts Humana (HUM) at In Line, PT $295, 'Counting Dollars, Counting Stars'
-
Raymond James Defending on Humana (HUM), PT $340: 'we think the recent pullback creates an attractive entry point into the stock'
-
UnitedHealth projects most Medicare Advantage members in top-rated plans by 2027
-
Humana expands musculoskeletal care with Vori Health and HOPCo partnerships
-
Humana (HUM) PT Raised to $322 at RBC Capital

